Eftozanermin Alfa Biosimilar – Anti-TRAILR2 fusion protein – Research Grade

Description of Eftozanermin Alfa Biosimilar - Anti-TRAILR2 fusion protein - Research Grade

Introduction

Eftozanermin Alfa Biosimilar, also known as Anti-TRAILR2 fusion protein, is a promising therapeutic agent that has been extensively studied for its potential in cancer treatment. This biosimilar is a fusion protein that combines the sequence of the human TRAILR2 receptor with the Fc region of an antibody, making it a potent anti- cancer agent with a unique mechanism of action. In this article, we will discuss the structure, activity, and potential applications of Eftozanermin Alfa Biosimilar in detail.

Structure of Eftozanermin Alfa Biosimilar

Eftozanermin Alfa Biosimilar is a recombinant fusion protein consisting of two main components: the extracellular domain of the human TRAILR2 receptor and the Fc region of an antibody. The TRAILR2 domain is responsible for the anti- cancer activity of this biosimilar, while the Fc region provides stability and prolongs its half-life in the body. The TRAILR2 domain is composed of four cysteine-rich repeats, which are essential for binding to its ligand, TRAIL (TNF-related apoptosis-inducing ligand). The Fc region, on the other hand, is derived from the constant region of an antibody and is responsible for binding to Fc receptors on immune cells, thereby activating their anti-tumor activity.

Activity of Eftozanermin Alfa Biosimilar Eftozanermin Alfa Biosimilar exerts its anti-

cancer activity through the TRAILR2 domain, which binds to TRAIL on the surface of cancer cells. This binding triggers a signaling cascade that leads to the activation of the apoptotic pathway, resulting in cell death. Unlike traditional chemotherapeutic agents, Eftozanermin Alfa Biosimilar specifically targets cancer cells without harming normal cells, making it a promising therapeutic option with minimal side effects. Moreover, the Fc region of this biosimilar also plays a crucial role in its activity by activating immune cells, such as natural killer cells and macrophages, to destroy cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

Therapeutic Target of Eftozanermin Alfa Biosimilar

The main therapeutic target of Eftozanermin Alfa Biosimilar is TRAILR2, a death receptor that is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer. TRAILR2 is a member of the tumor necrosis factor receptor (TNFR) superfamily and is involved in the regulation of cell death and survival. In cancer cells, TRAILR2 is often upregulated, leading to increased resistance to apoptosis and promoting tumor growth. By targeting TRAILR2, Eftozanermin Alfa Biosimilar can induce apoptosis in cancer cells, thereby inhibiting tumor growth and progression.

Applications of Eftozanermin Alfa Biosimilar

Eftozanermin Alfa Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. This biosimilar has the potential to be used as a monotherapy or in combination with other anti- cancer agents, such as chemotherapy and immune checkpoint inhibitors. Its unique mechanism of action and minimal side effects make it a promising therapeutic option for cancer patients who have failed conventional treatments. Moreover, Eftozanermin Alfa Biosimilar can also be used in research studies to investigate the role of TRAILR2 in cancer biology and to develop new treatment strategies targeting this receptor.

Conclusion

In summary, Eftozanermin Alfa Biosimilar is a fusion protein with a unique structure and mechanism of action that holds great potential in cancer treatment. Its ability to specifically target cancer cells and activate the immune system makes it a promising therapeutic option for various types of cancer. Further research and clinical trials